GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viking Therapeutics Inc (NAS:VKTX) » Definitions » Tax Expense

Viking Therapeutics (Viking Therapeutics) Tax Expense : $0.00 Mil (TTM As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Viking Therapeutics Tax Expense?

Viking Therapeutics's tax expense for the months ended in Mar. 2024 was $0.00 Mil. Its tax expense for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil.


Viking Therapeutics Tax Expense Historical Data

The historical data trend for Viking Therapeutics's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viking Therapeutics Tax Expense Chart

Viking Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Tax Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Viking Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Viking Therapeutics Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Viking Therapeutics  (NAS:VKTX) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


Viking Therapeutics Tax Expense Related Terms

Thank you for viewing the detailed overview of Viking Therapeutics's Tax Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Viking Therapeutics (Viking Therapeutics) Business Description

Traded in Other Exchanges
Address
9920 Pacific Heights Boulevard, Suite 350, San Diego, CA, USA, 92121
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Executives
Sarah Kathryn Rouan director 4995 BRADENTON AVENUE, SUITE 240, DUBLIN OH 43017
Greg Zante officer: Chief Financial Officer C/O SANGAMO BIOSCIENCES, INC STE-A-100, POINT RICHMOND TECH, 501 CANAL BLVD,, RICHMOND CA 94804
Rowland Charles A Jr director 3338 LANCASHIRE RD, FURLONG PA 18925
Lawson Macartney director C/O AMBRX, INC., 10975 N. TORREY PINES RD., LA JOLLA CA 92037
Brian Lian director, officer: President & CEO C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Marianna Mancini officer: Chief Operating Officer C/O VIKING THERAPEUTICS, INC., 12340 EL CAMINO REAL, STE 250, SAN DIEGO CA 92130
Matthew W Foehr director 11119 NORTH TORREY PINES RD #200, LA JOLLA CA 92037
Ligand Pharmaceuticals Inc 10 percent owner 3911 SORRENTO VALLEY BLVD, SUITE 110, SAN DIEGO CA 92121
Hiroko Masamune officer: Chief Development Officer C/O VIKING THERAPEUTICS, INC., 12340 EL CAMINO REAL, SUITE 250, SAN DIEGO CA 92130
Michael Morneau officer: Chief Financial Officer C/O TRIUS THERAPEUTICS, INC., 6410 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
J Matthew Singleton director 286 STANWICH ROAD, GREENWICH CT 06830
Stephen W Webster director C/O OPTIMER PHARMACEUTICALS, INC, 101 HUDSON STREET, SAN DIEGO CA 07302
Rochelle Hanley officer: Chief Medical Officer C/O VIKING THERAPEUTICS, INC., 11119 NORTH TORREY PINES ROAD, SUITE 50, SAN DIEGO CA 92037
Michael Dinerman officer: Chief Operating Officer C/O VIKING THERAPEUTICS, INC., 11119 NORTH TORREY PINES ROAD, SUITE 50, SAN DIEGO CA 92037